Sol-Gel Technologies (Sol-Gel Technologies) LT-Debt-to-Total-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sol-Gel Technologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sol-Gel Technologies's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.03.

Sol-Gel Technologies's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.03). It may suggest that Sol-Gel Technologies is progressively becoming more dependent on debt to grow their business.

Sol-Gel Technologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sol-Gel Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sol-Gel Technologies LT-Debt-to-Total-Asset Chart

Sol-Gel Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.03

Sol-Gel Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.03	0.03	0.03

Sol-Gel Technologies LT-Debt-to-Total-Asset Calculation

Sol-Gel Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.206	/	45.287
	=	0.03

Sol-Gel Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	1.133	/	39.911
	=	0.03

Sol-Gel Technologies (NAS:SLGL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sol-Gel Technologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sol-Gel Technologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sol-Gel Technologies (Sol-Gel Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sol-Gel Technologies Ltd (NAS:SLGL) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

4SG:Germany 4SG:Germany

Address

7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650

Website

https://www.sol-gel.com

Sol-Gel Technologies Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.